Physician profile
Barbara A Dune
NPI 1255644811
$13,625.67
in general payments reported to CMS, 2019-2025
23 companies · $3,279 in 2025
The $3,279 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,874 · 2020: $471 · 2021: $1,613 · 2022: $1,587 · 2023: $1,607 · 2024: $2,195 · 2025: $3,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,219 · Consulting Fee: $750 · Entertainment: $94.38 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,218.85 |
| Consulting Fee | $750.00 |
| Entertainment | $94.38 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,386.93 | 2019-2025 | Rocklatan, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $1,763.80 | 2022-2025 | Miebo, Xiidra, Infuse |
| Tarsus Pharmaceuticals, INC. | $1,587.11 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $1,566.87 | 2020-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $992.80 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $696.88 | 2019-2025 | Acuvue |
| Coopervision INC. | $582.28 | 2019-2024 | Myday Contact Lens |
| Allergan, INC. | $550.19 | 2019-2022 | |
| Oyster Point Pharma, INC. | $483.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $393.39 | 2022-2024 | Idose, Photrexa |
| Novo Nordisk INC | $369.12 | 2021 | |
| Dompe US, INC. | $364.29 | 2021-2025 | Oxervate |
| Sight Sciences, INC. | $358.62 | 2020-2023 | Tearcare System |
| Kala Pharmaceuticals, INC. | $357.91 | 2021-2022 | |
| Abbvie INC. | $261.81 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $243.91 | 2024-2025 | Vevye |
| Shire North American Group INC | $160.83 | 2019 | |
| Lkc Technologies, INC. | $139.23 | 2025 | |
| Eyevance Pharmaceuticals LLC | $136.49 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.40 | 2019 | |
| Optos, INC. | $94.38 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biotissue Holdings INC. | $15.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Dune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.